Ignite Creation Date:
2024-05-06 @ 7:51 PM
Last Modification Date:
2024-10-26 @ 3:15 PM
Study NCT ID:
NCT06168487
Status:
RECRUITING
Last Update Posted:
2024-05-16
First Post:
2023-12-04
Brief Title:
Telmisartan in Prostate Cancer
Sponsor:
Tyler J Curiel
Organization:
Dartmouth-Hitchcock Medical Center
Study Overview
Official Title:
Phase I Non-Randomized Unblinded Single-Center Trial of Oral Telmisartan Alone or Combined With Selected Standard of Care Therapies for Prostate Cancer
Status:
RECRUITING
Status Verified Date:
2024-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The goal of this clinical trial is to learn about the tolerability of telmisartan in patients with prostate cancer
Detailed Description:
The primary objective of this study is to test the tolerability of oral telmisartan given as a single agent or combined with specific standard of care agents in selected participants with PC Patients will be defined as tolerating telmisartan if they maintain systolic blood pressure 110 mm Hg and are without greater than grade 2 toxicities as defined in the Common Terminology Criteria for Adverse Events v51 for at least 60 days total telmisartan treatment
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
True
Is an FDA AA801 Violation?:
None